Join the Non-Small Cell Lung Cancer group to help and get support from people like you.
Non-Small Cell Lung Cancer News
Related terms: Cancer, Lung, Non-Small Cell, Lung Cancer, Non-Small Cell, NSCLC
Alecensa Approved as First and Only ALK Inhibitor for Non-Small Cell Lung Cancer
MONDAY, April 22, 2024 – The U.S. Food and Drug Administration has approved Alecensa (alectinib) as adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase...
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
South San Francisco, CA – April 18, 2024 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved ...
Adjuvant Alectinib Improves Disease-Free Survival in Lung Cancer
FRIDAY, April 12, 2024 – Adjuvant alectinib improves disease-free survival compared with platinum-based chemotherapy among patients with resected ALK-positive non-small cell lung cancer (NSCLC),...
Household Radon Can Lead to Lung Cancer -- Has Your Home Been Tested?
THURSDAY, April 11, 2024 – Kentucky resident Chasity Harney embraced a thoroughly healthy lifestyle – eating right, exercising and never touching tobacco. So, her 2018 diagnosis of advanced lung...
Rybrevant (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
RARITAN, New Jersey (March 01, 2024) – Johnson & Johnson (NYSE: JNJ) announced today that following a priority review, the U.S. Food and Drug Administration (FDA) has approved Rybrevant® (a...
Radon a Bigger Threat to Rural Homes
WEDNESDAY, Feb. 28, 2024 – Rural homeowners face a greater threat from odorless, radioactive radon gas than people living in urban areas, and it's likely due to the wells they rely on for their...
Tislelizumab Plus Chemotherapy Beneficial for Resectable NSCLC
FRIDAY, Feb. 23, 2024 – For patients with resectable non-small cell lung cancer (NSCLC), neoadjuvant tislelizumab (TIS) plus chemotherapy with adjuvant TIS yields significant benefit in terms of...
Tagrisso With the Addition of Chemotherapy Approved in the US for Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
19 February 2024 – AstraZeneca’s Tagrisso has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) n...
FDA Grants Traditional Approval to Tepmetko (tepotinib) for Metastatic Non-Small Cell Lung Cancer
On February 15, 2024, the Food and Drug Administration granted traditional approval to tepotinib (Tepmetko, EMD Serono, Inc.) for adult patients with metastatic non-small cell lung cancer (NSCLC)...
Pembrolizumab Improves Event-Free Survival in Early NSCLC
TUESDAY, Feb. 13, 2024 – For patients with early-stage non-small cell lung cancer (NSCLC), event-free survival (EFS) is improved with neoadjuvant pembrolizumab and chemotherapy, according to a study...
High-Frequency Jet Ventilation Seems Safe for Lung Ablation
MONDAY, Jan. 29, 2024 – For percutaneous lung ablation, high-frequency jet ventilation (HFJV) under general anesthesia seems as safe as spontaneous respiration (SR) under moderate sedation, with...
How Obamacare Boosted Lung Cancer Survival
TUESDAY, Jan. 16, 2024 – As more Americans with lung cancer gained access to quality care after passage of the Affordable Care Act (ACA), their post-surgical survival rates rose, new data shows. The...
Chemoradiation With SABR Boost Safe, Effective for Advanced Lung Cancer
TUESDAY, Jan. 16, 2024 – Chemoradiation with an adaptive stereotactic ablative radiotherapy (SABR) boost is safe and effective for patients with locally advanced, unresectable non–small cell lung c...
Treatment Approach Effective When Surgery Not an Option for Lung Cancer
FRIDAY, Jan. 12, 2024 – Lung cancer patients who are unsuitable candidates for surgery may have a new, effective treatment option, researchers report. In a small study – just 28 patients --...
Moderate-to-Vigorous Exercise Can Delay Mortality in Inoperable Lung Cancer
MONDAY, Jan. 8, 2024 – Higher device-measured moderate- to vigorous-intensity physical activity (MVPA) is associated with reduced 12-month mortality in people newly diagnosed with inoperable lung...
Ask a question
To post your own question to this support group, sign in or create an account.